The precise mechanism by which ofatumumab exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ofatumumab results in antibody-dependent cellular cytolysis and complement-mediated lysis.1 Learn more about the Mechanism of Action
DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; HCP, health care professional; IgG, immunoglobulin G; MOA, mechanism of action; MS, multiple sclerosis.
*Sample program is only available to patients who are determined to be appropriate candidates for treatment with KESIMPTA.
†Limitations apply. Offer not valid under Medicare, Medicaid, or any other federal or state health insurance program. Patients with commercial insurance coverage for KESIMPTA may receive up to $18,000 in annual copay benefits. Patients with commercial insurance and an initial denial of coverage may receive up to 12 months of free product while coverage is pursued. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions at start.kesimpta.com.